Capstone Therapeutics (NASDAQ:CAPS) & Mitsui & Co. (OTCMKTS:MITSY) Critical Analysis

Mitsui & Co. (OTCMKTS:MITSY – Get Free Report) and Capstone Therapeutics (NASDAQ:CAPS – Get Free Report) are both industrials companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, risk and earnings.

Analyst Ratings

This is a summary of current recommendations and price targets for Mitsui & Co. and Capstone Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mitsui & Co. 0 1 0 0 2.00
Capstone Therapeutics 1 0 0 0 1.00

Risk and Volatility

Mitsui & Co. has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500. Comparatively, Capstone Therapeutics has a beta of -1.5, meaning that its share price is 250% less volatile than the S&P 500.

Insider and Institutional Ownership

2.5% of Capstone Therapeutics shares are owned by institutional investors. 0.0% of Mitsui & Co. shares are owned by insiders. Comparatively, 39.3% of Capstone Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Mitsui & Co. and Capstone Therapeutics”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Mitsui & Co. $92.97 billion 1.00 $5.21 billion $42.41 15.29
Capstone Therapeutics $48.11 million 0.07 -$21.23 million ($3.35) -0.05

Mitsui & Co. has higher revenue and earnings than Capstone Therapeutics. Capstone Therapeutics is trading at a lower price-to-earnings ratio than Mitsui & Co., indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Mitsui & Co. and Capstone Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Mitsui & Co. 6.22% 10.67% 4.76%
Capstone Therapeutics -36.51% -144.43% -40.48%

Summary

Mitsui & Co. beats Capstone Therapeutics on 10 of the 12 factors compared between the two stocks.

About Mitsui & Co.

(Get Free Report)

Mitsui & Co., Ltd. operates as an trading and investment company worldwide. The company engages in the manufacture and sale of steel products; steel processing, maintenance, and recycling activities; investment, development, and trading of mineral and metal resources, as well as resource recycling and industrial developing solutions; and upstream development, logistics, and trading of energy resources, such as natural gas/LNG, oil, coal, and uranium. It also offers power, gas, water, rail, and logistics systems; sales, financing, lease, transportation, and logistics services; and invests in plants, offshore energy development, ships, aviation, space, railways, and automotives, as well as machinery for mining, construction, and industrial use. In addition, the company provides basic chemicals and inorganic raw materials, functional materials, electronic materials, specialty chemicals, housing and lifestyle materials, agri-inputs, animal/human nutrition, and health products; and logistics infrastructures services, including tank terminal operation, as well as plastic recycling and next-generation energy, such as hydrogen and ammonia and forest resources businesses. Further, it engages in the food resources and products, merchandising, retail, fashion and textiles, wellness, healthcare, pharma, hospitality, and human capital businesses. Additionally, it is involved in the ICT, finance, real estate, and logistics businesses. The company was incorporated in 1947 and is headquartered in Tokyo, Japan. Mitsui E&P Italia B operates as a subsidiary of Mitsui & Co., Ltd.

About Capstone Therapeutics

(Get Free Report)

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.

Receive News & Ratings for Mitsui & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mitsui & Co. and related companies with MarketBeat.com's FREE daily email newsletter.